CYP3A4 and prostate carcinoma: Polymorphic variations in androgen-regulatory genes may contribute to an increased susceptibility [39], and recent GWAS studies confirm correlations of biosynthesis and metabolic pathway variants, such as CYP17A1 and CYP3A4, with prostate cancer risk [40,41].